CD9:PA:PA- (EUR)

ETF | Others |

Last Closing

USD 178.58

Change

-0.86 (-0.48)%

Market Cap

USD 0.12B

Volume

1.51K
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-26 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

-0.06 (-0.13%)

USD 66.11B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

+1.60 (+0.31%)

USD 11.38B
WRD:PA HSBC ETFs Public Limited Compa..

+0.10 (+0.31%)

USD 9.27B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

-0.65 (-0.27%)

USD 7.87B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

+2.15 (+0.48%)

USD 7.42B
HHH:PA HSBC ETFs Public Limited Compa..

+0.15 (+0.30%)

USD 6.91B
WLD:PA Lyxor UCITS MSCI World D-EUR

+1.16 (+0.35%)

USD 6.48B
LCWD:PA Multi Units Luxembourg - Lyxor..

+0.05 (+0.27%)

USD 5.45B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

+1.46 (+0.40%)

USD 4.39B
500U:PA Amundi Index Solutions - Amund..

+0.53 (+0.50%)

USD 4.29B

ETFs Containing CD9:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.33% 50% F 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.33% 49% F 63% D
Trailing 12 Months  
Capital Gain 16.29% 64% D 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.29% 64% D 75% C
Trailing 5 Years  
Capital Gain 46.55% 61% D- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.55% 58% F 66% D+
Average Annual (5 Year Horizon)  
Capital Gain 8.75% 63% D 63% D
Dividend Return 8.75% 62% D 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.41% 61% D- 78% C+
Risk Adjusted Return 76.63% 87% B+ 90% A-
Market Capitalization 0.12B 35% F 49% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.